XML 47 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Summary of Significant Accounting Policies (Details) - USD ($)
3 Months Ended 12 Months Ended
Dec. 28, 2019
Sep. 28, 2019
Jun. 29, 2019
Mar. 30, 2019
Dec. 29, 2018
Sep. 29, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 28, 2019
Dec. 29, 2018
Dec. 30, 2017
Dec. 30, 2018
Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Net loss                 $ (29,374,222) $ (34,482,492) $ (25,380,115)    
Net Cash Provided by (Used in) Operating Activities                 (21,026,854) (28,103,782) (25,912,698)    
Revenue, Remaining Performance Obligation, Amount $ 9,300,000               9,300,000        
Revenues (8,727,000) $ (6,139,000) $ (9,110,000) $ (5,543,000) $ (7,741,000) $ (5,126,000) $ (5,944,000) $ (5,654,000) (29,518,809) (24,465,005) (27,841,490)    
Contract with Customer, Asset, after Allowance for Credit Loss 921,082               921,082       $ 3,089,663
Operating Lease, Right-of-Use Asset 2,753,963       0       $ 2,753,963 0      
Product Warranty Term                 12 months        
Inventory, Net, Items Net of Reserve Alternative [Abstract]                          
Raw materials 2,630,156       2,548,139       $ 2,630,156 2,548,139      
Work-in-process 711,475       1,526,552       711,475 1,526,552      
Finished goods 427,065       722,547       427,065 722,547      
Inventory (3,768,696)       (4,797,238)       (3,768,696) (4,797,238)      
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]                          
Asset retirement obligation, beginning balance       254,098       269,877 254,098 269,877      
Additional liabilities incurred                 7,785 (15,779)      
Asset retirement obligation, ending balance 261,883       254,098       261,883 254,098 269,877    
Impairment of Long-term Assets [Abstract]                          
Other assets 517,411       1,361,375       517,411 1,361,375      
Accumulated deficit (301,236,913)       (271,730,661)       (301,236,913) (271,730,661)      
Research and development and other revenues                 9,234,921 5,253,890 2,946,685    
Cost of product revenues                 20,901,538 15,831,441 18,118,418    
Net Income (Loss) Attributable to Parent $ (7,290,000) $ (6,625,000) $ (4,260,000) $ (11,331,000) (9,966,000) $ (9,791,000) $ (9,241,000) $ (5,536,000) $ (29,506,252) (34,533,542) $ (25,240,482)    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 12 months               12 months        
Operating Lease, Liability, Current $ 1,041,695       $ 0       $ 1,041,695 $ 0   $ 1,000,000.0  
Minimum                          
Property, Plant and Equipment [Abstract]                          
Useful life of property, plant and equipment                 3 years        
Maximum                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Operating Lease, Right-of-Use Asset                       3,700,000  
Property, Plant and Equipment [Abstract]                          
Useful life of property, plant and equipment                 10 years        
Impairment of Long-term Assets [Abstract]                          
Operating Lease, Liability                       $ 3,800,000  
Restricted stock                          
Stock-based Compensation [Abstract]                          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period                 645,000 1,549,000 1,152,000    
eMDT                          
Principles of Consolidations [Abstract]                          
Kopin's ownership percentage 80.00%               80.00%        
Share-based Payment Arrangement, Tranche One [Member]                          
Stock-based Compensation [Abstract]                          
Nonvested common stock awards employment obligations                 1 year        
Share-based Payment Arrangement, Tranche One [Member] | Restricted stock                          
Stock-based Compensation [Abstract]                          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period                 640,000        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period                 20 days        
Share-based Payment Arrangement, Tranche Two [Member]                          
Stock-based Compensation [Abstract]                          
Nonvested common stock awards employment obligations                 2 years        
Share-based Payment Arrangement, Tranche Two [Member] | Restricted stock                          
Stock-based Compensation [Abstract]                          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period                 150,000        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period                 20 days        
Share-based Payment Arrangement, Tranche Three [Member]                          
Stock-based Compensation [Abstract]                          
Nonvested common stock awards employment obligations                 4 years        
Share-based Payment Arrangement, Tranche Three [Member] | Restricted stock                          
Stock-based Compensation [Abstract]                          
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period                 150,000        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period                 20 days        
Unvested Restricted Stock Awards                          
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]                          
Antidilutive securities excluded from computation of earnings per share                 1,863,124 2,213,249 2,629,274    
Product [Member]                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Revenues                 $ (20,283,888) $ (19,211,115) $ (24,894,805)    
Impairment of Long-term Assets [Abstract]                          
Cost of product revenues                   15,831,441      
Net Income (Loss) Attributable to Parent                   $ (34,533,542)      
Extended Warranties [Member]                          
Impairment of Long-term Assets [Abstract]                          
Contract with Customer, Liability $ (39,000)               $ (39,000)        
Transferred over Time [Member]                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Revenue, Percentage from Products and Services Transferred to Customers                 64.00% 40.00% 9.00%    
Transferred at Point in Time [Member]                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Revenue, Percentage from Products and Services Transferred to Customers                 36.00% 60.00% 91.00%    
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]                          
Impairment of Long-term Assets [Abstract]                          
Cost of product revenues                   $ 346,176      
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Product [Member]                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Revenues                   (515,786)      
Impairment of Long-term Assets [Abstract]                          
Cost of product revenues                   977,902      
Net Income (Loss) Attributable to Parent                   115,940      
Calculated under Revenue Guidance in Effect before Topic 606 [Member]                          
Impairment of Long-term Assets [Abstract]                          
Cost of product revenues                   5,600,066      
Calculated under Revenue Guidance in Effect before Topic 606 [Member] | Product [Member]                          
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                          
Revenues                   (19,726,901)      
Impairment of Long-term Assets [Abstract]                          
Cost of product revenues                   16,809,343      
Net Income (Loss) Attributable to Parent                   $ (34,649,482)